title: Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants.
abstract: Poly(butyl cyanoacrylate) nanoparticles coated with poloxamer 188 (Pluronic) F68) and also, as shown previously, polysorbate 80 (Tween 80) considerably enhance the anti-tumour effect of doxorubicin against an intracranial glioblastoma in rats. The investigation of plasma protein adsorption on the surface of the drug-loaded nanoparticles by two-dimensional electrophoresis (2-D PAGE) revealed that both surfactants, besides other plasma components, induced a considerable adsorption of apolipoprotein A-I (ApoA-I). It is hypothesized that delivery of doxorubicin to the brain by means of nanoparticles may be augmented by the interaction of apolipoprotein A-I that is anchored on the surface of the nanoparticles with the scavenger receptor class B type I (SR-BI) located at the blood-brain barrier. This is the first study that shows a correlation between the adsorption of apolipoprotein A-I on the nanoparticle surface and the delivery of the drug across the blood-brain barrier.
authors.affiliation: Institute of Pharmacy, Free University of Berlin, 14195, Berlin, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Petri
authors.forename: A
authors.initials: A
authors.lastname: Bootz
authors.forename: A
authors.initials: A
authors.lastname: Khalansky
authors.forename: T
authors.initials: T
authors.lastname: Hekmatara
authors.forename: R
authors.initials: R
authors.lastname: Müller
authors.forename: R
authors.initials: R
authors.lastname: Uhl
authors.forename: J
authors.initials: J
authors.lastname: Kreuter
authors.forename: S
authors.initials: S
authors.lastname: Gelperina
mesh_terms: D000327:Adsorption; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use*; D016632:Apolipoprotein A-I / Q000378:metabolism; D001798:Blood Proteins / Q000737:chemistry; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003487:Cyanoacrylates; D003911:Dextrans; D004317:Doxorubicin / Q000008:administration & dosage* / Q000627:therapeutic use*; D004591:Electrophoresis, Polyacrylamide Gel; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology; D053758:Nanoparticles; D010316:Particle Size; D020442:Poloxamer; D051381:Rats; D013501:Surface-Active Agents / Q000737:chemistry*; D016019:Survival Analysis
chemical_list: D000903:Antibiotics, Antineoplastic; D016632:Apolipoprotein A-I; D001798:Blood Proteins; D003487:Cyanoacrylates; D003911:Dextrans; D013501:Surface-Active Agents; C116251:polyethylbutylcyanoacrylate; D020442:Poloxamer; D004317:Doxorubicin